Compound Cloud Library to be Screened in Programme Targeting Cyclic AMP Driven Kidney Disease
The aim of the programme is to develop a small molecule therapeutic to combat Autosomal Dominant Polycystic Kidney Disease (ADPKD), the kidney disease which is characterised by progressive cyst formation. ADPKD has knock-on health implications including high blood pressure, blood in urine, abdominal pain, kidney stones, urinary tract infections and ultimately kidney failure.
By screening a diverse, drug-like compound library from BioAscent’s Compound Cloud, the collaborators aim to develop a positive modulator of Phosphodiesterase 4 (PDE4) – the enzyme responsible for degradation of the messenger molecule cyclic AMP (cAMP). ADPKD is one of several diseases driven by elevated levels of cAMP; therefore by increasing the rate of PDE4 catalysed degradation of cAMP, the effects of these diseases can theoretically be reversed.
BioAscent will also provide iterative follow-up and validation for hits in the process of developing a lead molecule for this currently under-exploited protein class. For the compound library provided to the partnership, BioAscent was able to plate in a custom format onto acoustic liquid transfer microplates and deliver within less than a week of the order being placed.
Create your own library now using our Custom Library Creator:
BioAscent specialises in the management and logistics of screening compounds in support of drug discovery innovation. A state-of-the-art automated facility and expertise in commercial compound management enable the efficient reformatting, storage and distribution of millions of solid and liquid samples. BioAscent also runs Compound Cloud which is fast becoming the complete marketplace for screening libraries. Compound Cloud offers exciting compound sets from academic and biotech third parties as well as an in-house drug-like collection from which users can cherry-pick their own library. Created libraries can be custom formatted and delivered assay-ready within days.
Mironid® Limited, based in Scotland, UK, is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key PDE4 enzymes. The Company’s founders include Prof Miles Houslay who has spent over 30 years investigating the mechanisms of PDE biology while consulting for many of the world’s top Pharmaceutical companies including working with Celgene Corp to develop from inception the PDE4 inhibitor, Apremilast, which is used to treat psoriasis and psoriatic arthritis.
Sygnature operates a fully-enabled research facility in Nottingham, UK, with over 160 experienced scientists with the professional expertise required to take on board the most demanding of drug discovery projects and drive them towards a successful outcome. The company undertakes target validation, hit identification, hit-to-lead and lead optimisation projects. Sygnature’s capabilities include medicinal chemistry, bioscience, computational chemistry and DMPK. Since 2011 8 drug candidates, invented at Sygnature, have entered the clinic.
Peak Proteins Limited based at Alderley Park, Cheshire is a small recently formed CRO, specialising in high-quality production and purification of proteins in addition to structure determination by X-ray crystallography. The company is able to leverage several decades of prior pharmaceutical industry experience in successfully delivering protein reagents and X-ray crystal structures to a wide range of drug discovery projects.
Innovate UK is the UK’s innovation agency. Innovate UK is an executive non-departmental public body, sponsored by the Department for Business, Energy & Industrial Strategy, which works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. Since 2007, Innovate UK has committed over £1.8 billion to innovation, matched by a similar amount in partner and business funding. The agency has helped more than 7,600 organisations with projects estimated to add more than £11.5 billion to the UK economy and create 55,000 extra new jobs.